Tenderwize
Retour à la recherche

Non-exclusive Rebate Agreement for Tacrolimus

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Oct 31, 2027 · 429 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tacrolimus (ATC-Code nach WHO: D11AH01)

30/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

30 / 100

Complexité

30 / 100

Facteurs de risque

No minimum volume or purchase commitment; actual demand is uncertain and dependent on prescribing behavior and pharmacy...

The contracting authority may terminate the open-house procedure early if exclusive agreements are signed, ending exist...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Supply of pharmaceutical products containing Tacrolimus (ATC D11AH01)
  • Non-exclusive rebate agreement with AOK PLUS
Afficher le résumé complet

This tender is for non-exclusive pharmaceutical rebate agreements under an open-house model for the active substance Tacrolimus (ATC D11AH01), organized by AOK PLUS. It is not a formal public procurement but is published for transparency. Any qualified pharmaceutical company can join during the participation period, with the first deadline on 7 October 2025 and subsequent deadlines until 31 October 2027. Contract ends no later than 31 October 2027. No exclusivity, no minimum volume, and no guarantee of purchases. The rebate terms are confidential. Award is based solely on meeting participation conditions.

Risques

No minimum volume or purchase commitment; actual demand is uncertain and dependent on prescribing behavior and pharmacy...

The contracting authority may terminate the open-house procedure early if exclusive agreements are signed, ending exist...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company as defined in §4(18) AMG

Eligibility

  • Must provide self-declaration of no exclusion grounds (Sections 123, 124 GWB)

Administrative

  • Must provide declaration regarding Russia sanctions

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive Rebate Agreement for Tacrolimus

Non-exclusive rebate agreement for Tacrolimus (ATC D11AH01) under an open-house model. Any pharmaceutical company fulfilling conditions can join. No minimum volume or exclusivity. Contract period from 7 October 2025 to 31 October 2027.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Oct 2025 - Oct 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Oct 31, 2027

Détails de la procédure

Date de publication
28 Aug 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
565111-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30